These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 12860576

  • 1. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK, Williams GH, Anderson R, Akhras KS, Bittman RM, Krause SL.
    Arch Intern Med; 2003 Jul 14; 163(13):1543-8. PubMed ID: 12860576
    [Abstract] [Full Text] [Related]

  • 2. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA.
    Hypertension; 2003 May 14; 41(5):1021-6. PubMed ID: 12682082
    [Abstract] [Full Text] [Related]

  • 3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 May 14; 5(5):354-63. PubMed ID: 14503934
    [Abstract] [Full Text] [Related]

  • 4. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B, Patrick JL, Krause SL.
    Am Heart J; 2005 Sep 14; 150(3):426-33. PubMed ID: 16169319
    [Abstract] [Full Text] [Related]

  • 5. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH.
    Circulation; 2003 Oct 14; 108(15):1831-8. PubMed ID: 14517164
    [Abstract] [Full Text] [Related]

  • 6. Eplerenone: cardiovascular protection.
    Brown NJ.
    Circulation; 2003 May 20; 107(19):2512-8. PubMed ID: 12756192
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F, Rosano G, Patti G, Volterrani M, Greco C, Gaudio C.
    Int J Cardiol; 2015 Dec 01; 200():8-11. PubMed ID: 25466561
    [Abstract] [Full Text] [Related]

  • 8. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.
    Clin J Am Soc Nephrol; 2006 Sep 01; 1(5):940-51. PubMed ID: 17699311
    [Abstract] [Full Text] [Related]

  • 9. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
    Nakamura T, Fukuda M, Kataoka K, Nako H, Tokutomi Y, Dong YF, Yamamoto E, Yasuda O, Ogawa H, Kim-Mitsuyama S.
    Hypertens Res; 2011 Jul 01; 34(7):817-24. PubMed ID: 21471977
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E.
    J Am Coll Cardiol; 2003 Apr 02; 41(7):1148-55. PubMed ID: 12679215
    [Abstract] [Full Text] [Related]

  • 12. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Athyros VG, Mikhailidis DP.
    Expert Opin Pharmacother; 2008 Mar 02; 9(4):509-15. PubMed ID: 18312153
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Review article: eplerenone: an underused medication?
    Abuannadi M, O'Keefe JH.
    J Cardiovasc Pharmacol Ther; 2010 Dec 02; 15(4):318-25. PubMed ID: 20876342
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M.
    Am J Hypertens; 2004 Jun 02; 17(6):495-501. PubMed ID: 15177521
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.